Stock listing

Context Therapeutics Inc.

Selected listing: 6K9 · MUN · EUR · DE

Context Therapeutics Inc. (Munich:6K9), Health Technology. Latest release Sep 9, 2026: Context Therapeutics Announces First Patient Dosed in Phase 1 Trial…

6K9:MUNEURDEUpdated October 2, 2026

Ticker: Munich:6K9
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Munich
Currency: EUR

Latest news from Context Therapeutics Inc.

Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202

September 9, 2026

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

August 5, 2026

Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes

July 6, 2026

Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76

June 15, 2026

Context Therapeutics to Present at the Jefferies Global Healthcare Conference

May 27, 2026

All Context Therapeutics Inc. news →

Research Context Therapeutics Inc.

Context Therapeutics Inc. company profile

View the public company page for Context Therapeutics Inc. on 6ix.

Context Therapeutics Inc. news

Read company news and market updates connected to Context Therapeutics Inc..

Context Therapeutics Inc. investor events

Find investor webinars, events, and replay context for Context Therapeutics Inc..